DOCSLIB.ORG

Etats Rapides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Etats Rapides List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate 1281 Yes +5°C ± 3°C 79 ! Y0000086 Aceclofenac impurity H 1 10 mg 1 [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] oxy]acetyl]oxy] 1281 Yes +5°C ± 3°C 79 ! acetic acid Y0001094 Aceclofenac for peak identification 1 10 mg 1 1281 Yes +5°C ± 3°C 79 ! Y0000810 Acemetacin 1 100 mg 1 1686 Yes +5°C ± 3°C 79 ! Y0000811 Acemetacin impurity A 1 10 mg 1 4-chlorobenzoic acid 1686 Yes +5°C ± 3°C 79 ! Y0000842 Acemetacin impurity mixture 1 0.06 mg 1 1686 Yes +5°C ± 3°C 79 ! A0070000 Acesulfame potassium 2 50 mg 1 1282 Yes +5°C ± 3°C 79 ! A0070020 Acesulfame potassium impurity B 4 15 mg 1 see leaflet; 5-chloro-6-methyl-1,2,3-oxathiazin-4(3§)-one 2,2-dioxide 1282 Yes +5°C ± 3°C 79 ! A0100000 Acetazolamide 1 100 mg 1 0454 Yes +5°C ± 3°C 79 ! Y0001084 Acetazolamide for system suitability 2 0.0068 mg 1 Batch 1 is valid until 31 May 2015 0454 Yes +5°C ± 3°C 79 ! Y0000002 Acetylcholine chloride 1 50 mg 1 1485,1971 Yes -20°C ± 5°C 79 ! A0150000 Acetylcysteine 3 50 mg 1 0967 Yes +5°C ± 3°C 79 ! A0152000 Acetylcysteine impurity C 9 10 mg 1 See leaflet; N,N'-diacetyl-L-cystine 0967 Yes +5°C ± 3°C 79 ! A0153000 Acetylcysteine impurity D 6 10 mg 1 N,£-diacetyl-L-cysteine ; Batch 5 is valid until 28 May 2015 0967 Yes +5°C ± 3°C 79 ! Y0000565 ß-Acetyldigoxin 2 50 mg 1 See leaflet C÷–HÿÿOŒ— 2168 Yes +5°C ± 3°C 79 ! Y0000642 ß-Acetyldigoxin for peak identification 1 10 mg 1 2168 Yes +5°C ± 3°C 79 ! A0200000 Acetylsalicylic acid 4 15 mg 1 0309 Yes +5°C ± 3°C 79 ! Y0001460 Acetylsalicylic acid for peak identification 2 10.3 mg 1 0309 Yes +5°C ± 3°C 79 ! Y0001462 Acetylsulfadiazine 1 0.002 mg 1 0294 Yes +5°C ± 3°C 79 ! A0208000 N-Acetyltryptophan 2 125 mg 1 1383 Yes +5°C ± 3°C 79 ! © Council of Europe, all rights reserved 2015 1 For extra charges, please see supply terms and conditions. List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit A0202000 N-Acetyltyrosine 1 200 mg 1 1384 Yes +5°C ± 3°C 79 ! Y0000693 Acholeplasma laidlawii BRP 1 1 ml 1 20607 Yes -80°C ± 10°C 120 ! A0220000 Aciclovir 3 75 mg 1 0968 Yes +5°C ± 3°C 79 ! Y0001271 Aciclovir for peak identification 1 3 0.303 mg 1 0968 Yes +5°C ± 3°C 79 ! Y0001269 Aciclovir for peak identification 2 3 0.004 mg 1 Batch 2 is valid until 31 December 2014 0968 Yes +5°C ± 3°C 79 ! Y0001264 Aciclovir for system suitability 1 10 mg 1 0968 Yes +5°C ± 3°C 79 ! A0225000 Acitretin 2 100 mg 1 See leaflet CœŒHœÿO– 1385 Yes +5°C ± 3°C 79 ! Y0001463 Actaea racemosa HRS 1 1200 mg 1 2069 Yes +5°C ± 3°C 79 ! Y0001543 Actaea racemosa for assay CRS 1 300 mg 1 See leaflet C÷œHÿ—NOŒÿ; Monoammonium glycyrrhizate 2069 Yes +5°C ± 3°C 79 ! Y0001464 Actaea racemosa dry extract for system suitability HRS 1 1200 mg 1 2069 Yes -20°C ± 5°C 79 ! Y0001121 Adapalene 1 100 mg 1 See leaflet Cœ‡Hœ‡O– 2445 Yes +5°C ± 3°C 79 ! Y0001120 Adapalene impurity C 3 6 mg 1 1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane 2445 Yes +5°C ± 3°C 79 ! Y0001119 Adapalene for peak identification 2 2.022 mg 1 Batch 1 is valid until 31 March 2016 2445 Yes +5°C ± 3°C 79 ! A0230000 Adenine 2 50 mg 1 0800 Yes +5°C ± 3°C 79 ! A0230200 Adenosine 1 50 mg 1 1486 Yes +5°C ± 3°C 79 ! Y0000110 Adipic acid 1 50 mg 1 1586 Yes +5°C ± 3°C 79 ! Y0000882 Adrenaline 1 5 mg 1 2303 Yes +5°C ± 3°C 79 ! Y0000740 Adrenaline impurity mixture 3 0.0045 mg 1 0254,2303 Yes +5°C ± 3°C 79 ! Y0000883 Adrenaline with impurity F 1 10 mg 1 2303 Yes +5°C ± 3°C 79 ! A0300000 Adrenaline tartrate 5 100 mg 1 0254 Yes +5°C ± 3°C 79 ! Y0000707 Adrenaline tartrate with impurity A 1 15 mg 1 0254 Yes +5°C ± 3°C 79 ! Y0001724 Agnus castus fruit dry extract 1 350 mg 1 see leaflet 2309, 2147 Yes -20°C ± 5°C 79 ! A0325000 Alanine 3 60 mg 1 0752 Yes +5°C ± 3°C 79 ! A0325100 Albendazole 2 50 mg 1 Batch 1 is valid until 31 December 2015 1386 Yes +5°C ± 3°C 79 ! A0325200 Alcuronium chloride 2 50 mg 1 1285 Yes -20°C ± 5°C 79 ! A0325450 Alfacalcidol 9 5 mg 1 See leaflet ; Batch 8 is valid until 31 October 2015 1286 Yes -20°C ± 5°C 300 ! Y0001601 Alfacalcidol for system suitability 1 2.5 mg 1 1286 Yes -20°C ± 5°C 79 ! A0325451 Alfacalcidol - reference spectrum 1 n/a 1 1286 79 ! A1225000 Alfadex 3 150 mg 1 See leaflet [CÿHŒ!0—]ÿ 1070,1487 Yes +5°C ± 3°C 79 ! A0325500 Alfentanil hydrochloride - reference spectrum 1 n/a 1 1062 79 ! A0325800 Alfuzosin hydrochloride 2 10 mg 1 1287 Yes +5°C ± 3°C 79 ! Y0000832 Alfuzosin for system suitability 1 10 mg 1 1287 Yes +5°C ± 3°C 79 ! Y0001583 Alimemazine hemitartrate 1 15 mg 1 2650 Yes +5°C ± 3°C 79 ! Y0001581 Alimemazine for system suitability 1 5 mg 1 2650 Yes +5°C ± 3°C 79 ! A0349000 Allantoin 1 60 mg 1 1288 Yes +5°C ± 3°C 79 ! A0350000 Allopurinol 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 October 2015 0576 Yes +5°C ± 3°C 79 ! © Council of Europe, all rights reserved 2015 2 For extra charges, please see supply terms and conditions. List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit A0350010 Allopurinol impurity A 2 10 mg 1 5-amino-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 ! A0350020 Allopurinol impurity B 3 10 mg 1 5-formylamino-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 ! A0350030 Allopurinol impurity C 3 10 mg 1 5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 ! A0350040 Allopurinol impurity D 4 15 mg 1 ethyl 5-amino-1H-pyrazole-4-carboxylate ; Batch 3 is valid until 30 September 0576 Yes +5°C ± 3°C 79 ! 2015 A0350050 Allopurinol impurity E 1 20 mg 1 ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate 0576 Yes +5°C ± 3°C 79 ! A0351000 Allylstrychnine bromide 1 10 mg 1 1285 Yes -20°C ± 5°C 79 ! Y0000235 Almagate 1 25 mg 1 See leaflet 2010 Yes +5°C ± 3°C 79 ! Y0000255 Almagate - reference spectrum 1 n/a 1 2010 79 ! A0357000 Alprazolam - * psy 2 100 mg 1 1065 Yes +5°C ± 3°C 79 ! A0360000 Alprenolol hydrochloride 1 100 mg 1 0628,0876 Yes +5°C ± 3°C 79 ! Y0000054 Alprostadil 2 50 mg 1 see leaflet 1488 Yes -20°C ± 5°C 79 ! Y0000606 Altizide 2 150 mg 1 See leaflet CŒŒHŒ÷ClN–O÷S– 0370,2185 Yes +5°C ± 3°C 79 ! Y0000843 Altizide impurity B 1 15 mg 1 3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene 2185 Yes +5°C ± 3°C 79 ! Y0000687 Alverine citrate 1 5 mg 1 2156 Yes +5°C ± 3°C 79 ! Y0000607 Alverine impurity D 1 10 mg 1 N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine 2156 Yes +5°C ± 3°C 79 ! Y0000595 Alverine for peak identification 2 0.125 mg 1 2156 Yes -20°C ± 5°C 79 ! A0363000 Amantadine hydrochloride 1 100 mg 1 0463 Yes +5°C ± 3°C 79 ! A0363700 Ambroxol hydrochloride 3 125 mg 1 1489 Yes +5°C ± 3°C 79 ! A0900000 Amfetamine sulfate - reference spectrum 1 n/a 1 0368 79 ! A0365000 Amidotrizoic acid dihydrate 1 100 mg 1 0873 Yes +5°C ± 3°C 79 ! Y0001461 Amidotrizoic acid for system suitability 1 0.08 mg 1 0873 Yes +5°C ± 3°C 79 ! A0368000 Amikacin 3 200 mg 1 See leaflet 1289,1290 Yes +5°C ± 3°C 79 ! Y0001467 Amikacin impurity I 1 20 mg 1 (2S)-4-amino-2-hydroxybutanoic acid 1289, 1290 Yes +5°C ± 3°C 79 ! New Y0001117 Amikacin for system suitability 3 10 mg 1 1289,1290 Yes +5°C ± 3°C 79 ! A0365900 Amikacin sulfate 3 200 mg 1 The batch 3 is not suitable for use in the assay in monograph 1290:07/2014.
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • A Comparative Study of Neuromuscular Blocking Effects
    IndianJournalofAnesthesiaandAnalgesia OriginalResearchArticle January–February2020;7(1)(Part-I):58-63 DOI:http://dx.doi.org/10.21088/ijaa.2349.8471.7120.9 AComparativeStudyofNeuromuscularBlockingEffectsandReversibility ofCisatracuriumandVecuronium DivyaNKheskani1,HeenaSChhanwal2,BhaktiSJain3 1AssistantProfessor,2ProfessorandHead,3rdYearResident,DepartmentofAnaesthesia,GCSMedicalCollege,Hospital&Research Centre,NearChamundaBridge,Ahmedabad,Gujarat380025,India. Abstract Context: Cisatracurium is a cis isomer of parent compound atracurium, devoid of histamine release, thus possessing hemodynamic & cardiovascular stability. Aims: We compared the intubating conditions, hemodynamic stability & recovery of atracurium & vecuronium. Settings and Design: We carried out prospective, double blind randomized study after approval of ethical committee. 100 adult patients of ASA 1 &2with comparable demographicdatawereselected. Dividedin TwoGroupsC(Cisatracurium) &V(Vecuronium).Standardmonitoringwasdone&followingroutinepremedication&inductionagents, patientswereintubatedat2minsafteradministrationofcisatracurium0.15mg/kg&vecuronium0.1mg/ kgrespectively,maintainedonintermittentdoseofcisatracurium:0.03mg/kg&vecuronium:0.02mg/kg. IntubationconditionswereassessedaccordingtoTimeto25%recoveryoft1/tcfollowinginitialdoses,Time to25%recoveryoft1/tcfollowingrepeatedboluses,Timeto25%recoveryoft1/tcfollowinglastdose,Return oft4/t1ratio0.8spontaneousrecoveryatendofoperation.Statisticalanalysisused:Theresultswereevaluated byapplyingpairedt-testandp-valueusingSPSSStatisticalSoftware.Results:Intubatingconditionsat2mins
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Cost Analysis and Safety Comparison of Cisatracurium and Atracurium in Patients Undergoing General Anesthesia
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 447-450 Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia A. MOVAFEGH, S. AMINI*, H. SHARIFNIA, H. TORKAMANDI*, A. HAYATSHAHI*, M. JAVADI* Intensive Care Unit, and *Pharmaceutical Care Department; Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Abstract. – BACKGROUND : Non-depolarizing Introduction neuromuscular blocking agents (NMB) differ in pharmacokinetic and pharmacodynamic parame - The introduction of neuromuscular blocking ters. An anesthesiologist according to these simi - larities and differences is able to choose the least agents in 1942 into anesthetic practice was an im - costly one if the same safety profile and same clin - portant development. Non-depolarizing NMB ical benefit achieved with the different alternatives. agents differ in the onset of action, duration of ac - AIM: The main objective of this study is to eval - tion, metabolic route, potency, adverse effects and uate the economic and adverse drug reactions cost. An anesthesiologist is able to choose NMB prevalence and differences between cisatracurium drugs according to these similarities and differ - and atracurium the two non-depolarizing NMB 1,2 drugs, which are widely used in adult patients un - ences . Atracurium and Cisatracurium are two dergoing surgery with general anesthesia in a non-depolarizing NMB agents with intermediate teaching Hospital in Iran. duration of action 1. Cisatracurium besilate is the MATERIALS AND METHODS : A cost analysis R-cis isomer of atracurium besilate and is 3-4 fold and adverse drug reactions (ADR) monitoring more potent than atracurium 3. Compared with were performed.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 8Th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008
    Epilepsia, 50(Suppl. 4): 2–262, 2009 doi: 10.1111/j.1528-1167.2009.02063.x 8th ECE PROCEEDINGS 8th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008 Sunday 21 September 2008 KV7 channels (KV7.1-5) are encoded by five genes (KCNQ1-5). They have been identified in the last 10–15 years by discovering the caus- 14:30 – 16:00 ative genes for three autosomal dominant diseases: cardiac arrhythmia Hall 1 (long QT syndrome, KCNQ1), congenital deafness (KCNQ1 and KCNQ4), benign familial neonatal seizures (BFNS, KCNQ2 and VALEANT PHARMACEUTICALS SATELLITE SYM- KCNQ3), and peripheral nerve hyperexcitability (PNH, KCNQ2). The fifth member of this gene family (KCNQ5) is not affected in a disease so POSIUM – NEURON-SPECIFIC M-CURRENT K+ CHAN- far. The phenotypic spectrum associated with KCNQ2 mutations is prob- NELS: A NEW TARGET IN MANAGING EPILEPSY ably broader than initially thought (i.e. not only BFNS), as patients with E. Perucca severe epilepsies and developmental delay, or with Rolando epilepsy University of Pavia, Italy have been described. With regard to the underlying molecular pathophys- iology, it has been shown that mutations in KCNQ2 and KCNQ3 Innovations in protein biology, coupled with genetic manipulations, have decrease the resulting K+ current thereby explaining the occurrence of defined the structure and function of many of the voltage- and ligand- epileptic seizures by membrane depolarization and increased neuronal gated ion channels, channel subunits, and receptors that are the underpin- firing. Very subtle changes restricted to subthreshold voltages are suffi- nings of neuronal hyperexcitability and epilepsy. Of the currently cient to cause BFNS which proves in a human disease model that this is available antiepileptic drugs (AEDs), no two act in the same way, but all the relevant voltage range for these channels to modulate the firing rate.
    [Show full text]
  • Difference Between Patient-Reported Side Effects of Ciclesonide Versus fluticasone Propionate
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2010) 104, 1825e1833 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Difference between patient-reported side effects of ciclesonide versus fluticasone propionate Thys van der Molen a, Juliet M. Foster a,b, Manfred Caeser c,e, Thomas Mu¨ller c, Dirkje S. Postma d,* a Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands b Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe NSW 2037, Sydney, Australia c Nycomed GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Konstanz, Germany d Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands Received 18 January 2010; accepted 26 May 2010 Available online 2 July 2010 KEYWORDS Summary Adverse events; Rationale: Patient-reported outcomes provide new insights into the dynamics of asthma Inhaled corticosteroid management. Further to asthma control and quality of life, self-reported side effects of treat- questionnaire; ment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ). ICQ; Objectives: To compare patient-reported side effects between the inhaled corticosteroids Patient-reported ciclesonide and fluticasone propionate. outcomes Methods: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant dose and type of medication, were randomized in three separate studies: 1) once daily cicle- sonide 320 mg(n Z 234) or twice daily fluticasone propionate 200 mg(n Z 240); 2) twice daily ciclesonide 320 mg(n Z 255) or twice daily fluticasone propionate 375 mg(n Z 273); and 3) twice daily ciclesonide 320 mg(n Z 259) or twice daily fluticasone propionate 500 mg (n Z 244).
    [Show full text]